Abstract: Oligometastatic patients are a heterogeneous and yet not well-defined population. The actual definition identifies as oligometastatic, patients with 1– 5 metastases in 1– 3 different organs. However, only a proportion of these patients are “true” oligometastatic and therefore derive some kinds of benefit from local ablative approaches like stereotactic ablative radiation therapy (SABR). Since SABR is an easily accessible, effective and well-tolerated treatment, it is widely employed in the oligometastatic scenarios, without a particular focus on selection criteria. However, it should be crucial to identify predictive and prognostic features that could be clinically implemented. Therefore, we conducted this narrative review of the available literature to summarize all clinical, radiomic, genetic and epigenetic features found to be predictive of overall survival, progression-free survival or local control of oligometastatic patients treated with SABR.

Keywords: stereotactic ablative radiation therapy, oligometastases, prognostic factors, selection criteria


中文翻译：

---

了解何时在寡转移癌中使用立体定向消融放射治疗

摘要：寡转移患者是一个异质性但尚未明确定义的人群。实际定义为寡转移，患者在 1-3 个不同器官中有 1-5 个转移灶。然而，这些患者中只有一部分是“真正的”寡转移，因此从局部消融方法如立体定向消融放射治疗 (SABR) 中获得某些益处。由于 SABR 是一种易于获得、有效且耐受性良好的治疗方法，因此它被广泛用于寡转移情况，而没有特别关注选择标准。然而，确定可以在临床上实施的预测和预后特征应该是至关重要的。因此，我们对现有文献进行了叙述性审查，以总结所有临床、放射学、

关键词：立体定向消融放疗，寡转移，预后因素，选择标准